Defining regulators of immunity to acute infection using CRISPR screens

使用 CRISPR 筛选定义急性感染免疫调节因子

• 批准号: 10266219
• 负责人: Arlene H. Sharpe
• 金额: $ 10.99万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-05 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10266219
• 关键词: Autoimmunity; Bioinformatics; Boston; CD4 Positive T Lymphocytes; CD8B1 gene; CRISPR library; CRISPR screen; CRISPR/Cas technology; Candidate Disease Gene; Cell physiology; Cells; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; Communicable Diseases; Complement; Computer Models; Computer software; Custom; Dana-Farber Cancer Institute; Data Analyses; Dendritic Cells; Development; Disease; Disease model; Foundations; Gene Expression; General Hospitals; Genes; Genetic Screening; Genomic DNA; Genomics; Goals; Guide RNA; Hematopoietic; Hospitals; Human; Hypersensitivity; Immune; Immune response; Immune system; Immunity; Immunotherapy; Infection; Institutes; Massachusetts; Mediating; Methods; Modeling; Mus; Pathway interactions; Pediatric Hospitals; Phenotype; Pilot Projects; RNA library; Regimen; Research Personnel; Research Project Grants; Standardization; System; T-Lymphocyte; Testing; Translations; Vaccine Adjuvant; Vaccines; Validation; Woman; acute infection; adaptive immune response; base; computerized tools; data management; data sharing; design; experimental study; genetic manipulation; immune function; immunoregulation; in vivo; innovation; insight; interest; loss of function; medical schools; novel; novel strategies; pathogen; programs; response; single cell analysis; single-cell RNA sequencing; tool; vaccination strategy; validation studies

The overarching goal of this U19 Program is to use forward genetic screens in mice to advance our understanding of immune responses to pathogens. This U19 Program is driven by our recent development of a genetic screening platform that uses pooled, in vivo CRISPR-mediated loss-of- function genetic screens to identify genes that positively or negatively regulate the fate and function of immune cells. We will couple this novel approach with single-cell gene profiling and systems-level computational modeling of innate and adaptive cells during acute infection to nominate candidates to perturb functionally in genetic screens. We will then test thousands of potential regulators in pooled CRISPR-Cas9 based forward genetic screens in mice, and validate novel candidate regulators in mouse infection models and human cells. Our proposed U19 Program consists of 2 highly interactive Projects, supported by 4 Cores. Project 1 (Haining/Kuchroo/Sharpe) will conduct forward genetic screens to identify genes that regulate the fate and function of CD8+ and CD4+ T cells responding to acute infection. Project 2 (Hacohen/Kagan) will conduct screens to identify genes that control DC activation in response to pathogens, pathogen components and T cells. Administrative Core A (Sharpe/Haining) will provide administrative and scientific coordination, and implement our Pilot Project program. Data Management and Bioinformatics Core B (Regev) will develop, apply and disseminate cutting-edge methods and tools for single cell RNA-seq analysis of immune cell responses and for selecting and ranking candidate genes for genetic manipulation in CRISPR screens. Core B will also establish and maintain a public portal and software pipelines for sharing data, analyses and methods. CRISPR Library Core C (Doench) will design and generate custom single guide RNA (sgRNA) libraries needed to conduct forward genetic screens and to validate candidate regulators. Core C will also analyze genomic DNA from cells obtained pooled screens, performing sequencing and sequence deconvolution to identify sgRNAs that caused the phenotype of interest. Mouse Perturbation Core D (Sharpe/Haining) will provide a uniform platform to execute CRISPR-Cas9 screens and validation experiments in mouse infection models. The use of standardized experimental methods and computational tools by the cores will make it possible to compare and integrate results in different settings and disease models. We expect that our in vivo forward genetic screens and systems level single-cell genomic analyses will identify the central molecules, pathways and mechanism that guide innate and adaptive immune responses to infection. These findings will lay the foundation for new vaccination strategies for infectious diseases and therapies for allergy and autoimmunity.

这个U19项目的首要目标是利用小鼠的前向基因筛选来推进我们的研究

项目成果

Framework for in vivo T cell screens.

• DOI: 10.1084/jem.20230699
• 发表时间: 2024-02
• 期刊: The Journal of experimental medicine
• 作者: Lauren E Milling;Samuel C. Markson;Qin Tjokrosurjo;Nicole M Derosia;Ivy S L Streeter;Grant H Hickok;Ashlyn M Lemmen;Thao H Nguyen;Priyamvada Prathima;William Fithian;Marc A. Schwartz;N. Hacohen;John G Doench;M. LaFleur;Arlene H. Sharpe

IL-18: throwing off the shackles to boost anti-tumor immunity.

• DOI: 10.1038/s41422-020-00396-3
• 发表时间: 2020-10
• 期刊: Cell research
• 影响因子: 44.1
• 作者: Dixon KO;Kuchroo VK
• 通讯作者: Kuchroo VK

Author Correction: The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity.

作者更正：共抑制受体的阴阳：朝向无自身免疫的抗肿瘤免疫。

• DOI: 10.1038/s41422-020-0285-x
• 发表时间: 2020
• 期刊: Cell research
• 影响因子: 44.1
• 作者: Schnell,Alexandra;Bod,Lloyd;Madi,Asaf;Kuchroo,VijayK
• 通讯作者: Kuchroo,VijayK

CRISPR Screens to Identify Regulators of Tumor Immunity.

• DOI: 10.1146/annurev-cancerbio-070120-094725
• 发表时间: 2022-04
• 期刊: ANNUAL REVIEW OF CANCER BIOLOGY
• 影响因子: 7.7
• 作者: LaFleur, Martin W.;Sharpe, Arlene H.
• 通讯作者: Sharpe, Arlene H.

Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells.

• DOI: 10.1073/pnas.2007935117
• 发表时间: 2020-12-01
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1
• 作者: Hu D;Tjon EC;Andersson KM;Molica GM;Pham MC;Healy B;Murugaiyan G;Pochet N;Kuchroo VK;Bokarewa MI;Weiner HL
• 通讯作者: Weiner HL